Acclimatization Mechanisms During Ascent to 7500m

This study has been completed.
Sponsor:
Collaborator:
Swiss National Science Foundation
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00603122
First received: January 15, 2008
Last updated: May 18, 2014
Last verified: May 2014
  Purpose

The trial evaluates the role of ascent protocol on acute mountain sickness and cardio-respiratory physiology during an ascent to Muztagh Ata (7546m). Two groups of mountaineers ascend with different acclimatization time to the summit. The prevalence and severity of symptoms of acute mountain sickness are evaluated along with physiologic variables.


Condition Intervention
Acute Mountain Sickness
Behavioral: ascent protocol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Acclimatization Mechanisms During Ascent to 7500m. Effects of Ascent Protocol on Acute Mountain Sickness and Cardiorespiratory Physiology

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • acute mountain sickness [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • mountaineering success, oxygen saturation, breathing pattern [ Time Frame: during ascent ] [ Designated as safety issue: No ]

Enrollment: 37
Study Start Date: March 2005
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
fast ascent
Behavioral: ascent protocol
ascent protocol for the two groups has different acclimatization time
Active Comparator: 2
slow ascent
Behavioral: ascent protocol
ascent protocol for the two groups has different acclimatization time

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy, physically fit subject
  • Mountaineering experience

Exclusion Criteria:

  • Any type of cardiac or respiratory disease
  • Regular intake of any medication
  • History of high altitude pulmonary oedema
  • Severe acute mountain sickness at altitudes below 3500m or high altitude cerebral oedema.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00603122

Sponsors and Collaborators
University of Zurich
Swiss National Science Foundation
Investigators
Principal Investigator: Konrad E Bloch, MD Pulmonary Division, University Hospital of Zurich, Zurich, Switzerland
  More Information

Publications:
Responsible Party: Konrad E. Bloch, University Hospital Zurich
ClinicalTrials.gov Identifier: NCT00603122     History of Changes
Other Study ID Numbers: EK-1189, SNSF 3200B0-108300
Study First Received: January 15, 2008
Last Updated: May 18, 2014
Health Authority: Switzerland: Swissmedic

Keywords provided by University of Zurich:
altitude illness
hypoxia

Additional relevant MeSH terms:
Altitude Sickness
Respiration Disorders
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 18, 2014